secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0000879407-26-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead reports Phase 1/2a data: ARO-INHBE + tirzepatide doubles weight loss in obese T2DM patients
--------------------------------------------------------------------------------

- ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.
- ARO-INHBE monotherapy: single dose reduced visceral fat -9.9% at week 16; two doses gave -15.6% placebo-adjusted at week 24.
- ARO-ALK7 is first RNAi to silence an adipocyte gene; mean ALK7 mRNA reduction -88% at 200 mg; visceral fat -14.1% at week 8.
- Both candidates generally well tolerated; no discontinuations; one unrelated SAE (limb abscess) in ARO-INHBE group.
- Company expects additional results from these ongoing Phase 1/2a studies later in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000004/0000879407-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000004/arwr-20260106.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer